Development of the first geldanamycin-based HSP90 degraders
Despite the early clinical promise, adverse events such as acquired resistance and dose-limiting toxicities have barred the widespread use of HSP90 inhibitors as anticancer drugs. A new approach involving proteolysis-targeting chimeras (PROTACs) to degrade the protein instead of inhibiting it may ov...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2023-06-01
|
| Colección: | Frontiers in Chemistry |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fchem.2023.1219883/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|